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Abstract

Author Manuscript

The host immune system is known to influence mesenchymal stem cell (MSC)-mediated bone
tissue regeneration. However, the therapeutic capacity of hydrogel biomaterial to modulate the
interplay between MSCs and T-lymphocytes is unknown. Here it is shown that encapsulating
hydrogel affects this interplay when used to encapsulate MSCs for implantation by hindering the
penetration of pro-inflammatory cells and/or cytokines, leading to improved viability of the
encapsulated MSCs. This combats the effects of the host pro-inflammatory T-lymphocyte-induced
nuclear factor kappaB pathway, which can reduce MSC viability through the CASPASE-3 and
CAS-PASE-8 associated proapoptotic cascade, resulting in the apoptosis of MSCs. To corroborate
rescue of engrafted MSCs from the insult of the host immune system, the incorporation of the antiinflammatory drug indomethacin into the encapsulating alginate hydrogel further regulates the
local microenvironment and prevents pro-inflammatory cytokine-induced apoptosis. These
findings suggest that the encapsulating hydrogel can regulate the MSC-host immune cell interplay
and direct the fate of the implanted MSCs, leading to enhanced tissue regeneration.

1. Introduction

Author Manuscript

Repair and regeneration of craniofacial bone defects have been widely achieved with bone
grafting procedures.[1–3] However, several disadvantages are associated with this treatment
modality,[4–7] making bone regeneration using mesenchymal stem cells (MSCs) an
advantageous alternative therapeutic option.[4–6]
Biomaterials have been utilized to control and manipulate the fate of stem cells leading to
high quality tissue regeneration.[9,10] However, controlling the fate of the transplanted stem
cells is still a major challenge. Biomaterial-MSC interactions have largely been studied by
encapsulating the cells within hydrogel biomaterials.[11,12] In bone tissue engineering, the
biomaterials have an essential role in the presentation of the physiological niche for MSCs
allowing encapsulated MSCs viability, and regulating their function and fate.

Author Manuscript

Studies have confirmed that host pro-inflammatory T-lymphocytes are able to inhibit MSCmediated bone regeneration through IFN-γ-(Interferon gamma) induced downregulation of
osteogenic regulators (e.g., RUNX2), upregulation of Smad 6, and enhancement of TNF-α
(tumor necrosis factor alpha) signaling, which induces cell apoptosis.[7,8] However, it is
unknown to what extent an implanted biomaterial and its physiochemical properties can
serve to regulate the interaction between the MSCs and the host immune system.[13,14] It is
possible that an encapsulating hydrogel biomaterial, especially in the early stages of
implantation, can physically protect implanted MSCs from the host immune cell/cytokine
insult and regulate the crosstalk between immune cells and MSCs. Given the increased use
of ionically crosslinked hydrogels for stem cell encapsulation,[15–17] it is important to
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understand the mechanisms that the encapsulating hydrogel uses to regulate the MSC-host
immune system interplay and to modulate the fate of the encapsulated stem cells.
Here, we report that alginate hydrogel, as an example of encapsulating biomaterial, affects
this interplay when used to encapsulate MSCs for implantation by hindering the penetration
of pro-inflammatory cells and/or cytokines, leading to improved viability of the
encapsulated MSCs. Our findings suggest that the encapsulating hydrogel depending on its
physiochemical properties (e.g., pore size) can affect MSC viability, function and therefore
regulate the MSC-host immune cell interplay and direct the fate of the implanted MSCs,
leading to enhanced tissue regeneration.

2. Results
Author Manuscript

2.1. Host Pro-Inflammatory T-Lymphocytes and Cytokines Inhibit Bone Marrow
Mesenchymal Stem Cell (BMMSC)-Mediated Bone Regeneration

Author Manuscript

To address our research question, we encapsulated human bone marrow (hBM) MSCs in
RGD (Arginylglycylaspartic acid)-coupled alginate hydrogel and subcutaneously implanted
the resultant microspheres into either C57BL6/J wild type (WT) or immunocompromised
(nude) mice. Unexpectedly, we found new bone formation in alginate-BMMSC implants in
WT mice (Figure 1a1,2,b1,b2), an outcome which was not found when BMMSCs were
implanted with the gold standard scaffold (hydroxyapatite/tricalcium phosphate (HA/TCP),
Zimmer Inc.) (Figure 1 a3,b3) or absorbable collagen sponge (ACS) carrier (Figure S1a8,
Supporting Information). To confirm the protective role of alginate hydrogel, we utilized it
to encapsulate MSCs from another source, namely stem cells from human exfoliated
deciduous teeth (SHED). A similar amount of bone to that observed with alginate-BMMSCs
implants was formed by SHED encapsulated in alginate when implanted in WT mice
(Figure S1a1–a8, Supporting Information), suggesting that the protective role of alginate is
not limited to BMMSCs and might be common to other stem cell types. These data indicated
that alginate hydrogel can partially protect MSCs against insult from the host immune
system when used as a carrier.
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Therefore, we hypothesized that the alginate hydrogel protects the encapsulated MSCs
against insult from host pro-inflammatory cells and cytokines. To examine this hypothesis,
we intravenously infused immunocompromised mice with 1 × 106 pro-inflammatory cells of
different types, including Pan T cells, CD4+ IL17+ (Th17) cells, and macrophages. We
subcutaneously implanted alginate-BMMSC microspheres into the same mice and after 8
weeks, the specimens were harvested. We found that Pan T cells and Th17 cells, but not
macrophages, dramatically inhibited bone formation when compared to a control group of
immunocompromised mice that did not receive any pro-inflammatory cells (Figure 1 a4–
6,b4–b6). These data indicate that pro-inflammatory T-lymphocytes pose a major threat to
the success of BMMSC-mediated bone regeneration (Figure 1 c,d). To confirm this finding,
we intravenously infused 1 × 106 CD4 +CD25 + Foxp3+ regulatory T cells (Tregs) into WT
mice, to reverse the pro-inflammatory action of the endogenous T-lymphocytes. We found
that bone formation was significantly increased compared to a WT control group that
received no Tregs (Figure 1 a7,8,b7,8). These data prompted us to examine whether alginate
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hydrogel delays the infiltration of the pro-inflammatory T-lymphocytes and/or cytokines
into the microspheres.
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It is well known that interactions between MSCs and biomaterials strongly influence MSC
viability, morphological characteristics, and differentiation in therapeutic applications.[18,19]
Therefore, understanding these interactions is of the utmost importance to ensure highquality tissue regeneration. It has been shown that differentiation of encapsulated MSCs
within ionically crosslinked alginate hydrogels is dictated by matrix stiffness, regulating the
fate of the MSCs regardless of cell morphology.[15–22] Our studies (Figure S2a–d,
Supporting Information) and others[18,19] have confirmed that the modulus of elasticity of
the encapsulating biomaterial regulates the stem cell lineage differentiation in 3D cultures.
Additionally, changes in the macromolecular diffusion characteristics of hydrogel
biomaterials are not responsible for the sensitivity of encapsulated MSCs to the elastic
modulus of the encapsulating biomaterial.[23,24] Hence, through diffusion rate analysis, we
found that changes in the elastic modulus of the alginate hydrogel also affected the
permeability of the hydrogel and thus modified its diffusion rate (Figure S2e,f, Supporting
Information). Based on these empirical outcomes, it was decided to utilize alginate hydrogel
with intermediate stiffness (E = 22 kPa) in order to achieve the lowest diffusion rate and
therefore the greatest protection for the encapsulated MSCs to promote osteogenic
differentiation. The other important physical properties of the encapsulating biomaterial that
has significant role of the viability and fate of the encapsulated cells is the porosity of the
biomaterials itself. Our previous studies confirmed that the alginate scaffold possesses a
porous structure, with 600 nm average pore size (120 nm to 1 μm range), making it a
selective barrier for cytokines and/or T-lymphocytes; this stands in contrast to ACS, which
possesses an average pore size of 200 μm. Therefore, it can be envisioned that alginate
hydrogel can act as a physical barrier to slow down the penetration of the pro-inflammatory
cytokines into the microspheres.
2.2. The Encapsulating Biomaterial Hinders the Infiltration of Pro-Inflammatory Cytokines

Author Manuscript

To evaluate the ability of alginate hydrogel to physically prevent and delay the infiltration of
pro-inflammatory cytokines, the permeability of the alginate hydrogel to two representative
cytokines, TNF-α and IL-17, was evaluated in vitro with ACS being used as the control
scaffold. Each of the scaffolds was immersed for 3 or 7 days in a 2 mL solution containing
200 μg mL−1 of either IL-17 or TNF-α. The amount of each cytokine that diffused into the
tested scaffolds was tracked over time using fluorescent microscopy. Our data (Figure 2 a,b)
clearly demonstrated that the initial penetration of cytokines into the microstructure of
alginate hydrogel, is hindered, thereby protecting the encapsulated MSCs. We observed that
greater amounts of cytokines were able to penetrate the ACS scaffold in comparison to the
alginate hydrogel (P < 0.01) (Figure 2 c,d). The amount of TNF-α that penetrated each
material was slightly lower than that of IL-17 at both time points, perhaps due to its larger
molecular weight/size (52 vs 35 kDa, respectively). However, no significant difference in
penetration for either cytokine was observed after 14 days of immersion (P > 0.05). Taken
together, these data confirm that alginate hydrogel can act as a physical barrier hindering the
initial penetration of pro-inflammatory cytokines (e.g., TNF-α and IL-17), protecting
encapsulated MSCs from cytokines elaborated by the host immune system. Moreover, as a
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prove of concept study, another type of nanoporous hydrogel system (poly ethylene glycol
dimethacrylate, PEGDMA, Sigma, St Louis, Mo) was used to confirm the protective
properties of hydrogel biomaterials is dependent on the porosity of the scaffolds which
regulates their permeability against pro-inflammatory cytokines and cells. The utilized
PEGMDA hydrogel has a comparable porous structure to alginate hydrogel with pore size
ranging from of 500 nm to 1 μm.
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To further characterize the permeability of the utilized scaffolds and in order to confirm our
obtained data, ELISA analysis was used. Briefly, each of the scaffolds were immersed for 3
or 7 days in a 2 mL solution containing 200 μg mL−1 of either IL-17 or TNF-α. After 3 and
7 days the scaffolds were removed, washed (×3) with distilled water, dissolved, and dried.
The concentration of the either of cytokines were analyzed using IL-17 and TNF-α ELISA
kits (both from BioLegend, San Diego, CA), respectively. Results (Figure 2 e,f) were in
good correlation with the abovementioned fluorescence microscopy data demonstrating that
a nanoporous hydrogel (alginate and PEGDMA) can hinder the initial penetration of proinflammatory cytokines (TNF-α and IL-17) in comparison to a macro-porous scaffold such
as ACS.
2.3. Alginate Hydrogel Reduces Apoptosis of Implanted BMMSCs via Reduction of ProInflammatory T-Lymphocyte Penetration

Author Manuscript

Next, we examined whether alginate is selectively impermeable to host inflammatory cells
in vivo. We encapsulated BMMSCs in either alginate hydrogel or ACS and subcutaneously
implanted them into WT mice for 3 or 7 days. Using immunofluorescence analysis, we
found that the infiltration of CD3+, CD4+, and CD4+ IL17+ T-lymphocytes in ACS was
significantly greater after 3 and 7 days of implantation in comparison to the alginate scaffold
(Figure 3a–f). Importantly, alginate hydrogel was better at preventing pro-inflammatory Tlymphocyte infiltration than the ACS scaffold (Figure 3 a–d). Given the deleterious effects
of pro-inflammatory T-lymphocytes on MSC-mediated bone regeneration, this outcome
suggests that the alginate hydrogel biomaterial has favorable properties as a carrier for
therapeutic delivery and retention of MSCs.

Author Manuscript

Since we previously demonstrated that apoptosis of implanted BMMSCs resulted in failed
bone regeneration,[7] we sought to determine whether pro-inflammatory T-lymphocyte
infiltration compromised BMMSC constructs by inducing the MSCs to undergo apoptosis.
Histoimmunofluorescence assays showed increased colocalization of CD146+ BMMSCs
with the apoptotic marker Annexin V in ACS scaffolds implanted in WT mice for 3 or 7
days (Figures 3 e and 2f), while the alginate hydrogel significantly reduced the number of
apoptotic (CD146+ AnnexinV+) BMMSCs observed (Figures 3e and 2f). Altogether, these
data provide evidence that the alginate hydrogel scaffold can protect BMMSCs from
apoptosis by inhibiting pro-inflammatory T-lymphocyte infiltration, leading to increased
MSC viability. In order to confirm our findings and demonstrate that these finding are not
unique only to alginate hydrogels, MSCs were encapsulated in another type of hydrogel
biomaterial, PEGMDA, with the same porosity characteristics as alginate hydrogel. Results
(Figure 3) clearly demonstrate that the encapsulating hydrogel exhibit protective properties,
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which is attributed to hindering the infiltration of pro-inflammatory T-lymphocytes,
protecting MSC from apoptosis.
2.4. Pro-Inflammatory Cytokines Induce BMMSC Apoptosis and Reduce their Osteogenic
Capacity

Author Manuscript

To identify whether pro-inflammatory T cells induce BMMSC apoptosis, leading to reduced
osteogenic capacity, our experimental strategy was to coculture BMMSCs with Th17 or a
Pan T cells for 2 days, followed by flow cytometry analysis to examine the percentage of
apoptotic BMMSCs identified as double positive for AnnexinV+ 7AAD+. We found that
pro-inflammatory cytokines indeed significantly increased the rate of BMMSC apoptosis
(Figure 4a). To confirm the link between cytokine-induced BMMSC apoptosis and reduced
osteogenic capacity, we cocultured BMMSCs with IL-17 or a combination of TNF-α and
INF-γ in vitro under osteogenic conditions. We observed that BMMSCs treated with these
cytokines exhibited decreased osteogenic differentiation, as indicated by Alizarin red
staining of mineralized nodule formation (Figure 4b). As expected, gene expression analysis
revealed downregulated expression of the osteogenic-associated genes alkaline phosphatase
(ALP) and runt-related transcription factor 2 (RUNX 2) (Figure 4c).
2.5. Pro-Inflammatory Cytokines Activated CASPASE-Dependent Apoptotic Pathway
through Nuclear Factor KappaB (NF-kB) Cascades in BMMSCs

Author Manuscript
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Our obtained data prompted us to assess whether the apoptotic cascade was induced by proinflammatory cytokines. Previous studies have shown that pro-inflammatory cytokines from
both Th17 and Th1 cells can induce NF-kB pathway activity.[25–29] Therefore, we examined
whether NF-kB cascades were activated in BMMSCs after treatment with either IL-17 or a
combination of TNF-α and INF-γ. Western blot analysis showed that the levels of proteins
associated with the NF-kB cascade, including p-IkB kinase a (p-IKKa), p-IkB, and p-NFkB, were significantly elevated in BMMSCs after either treatment (Figure 5a). Furthermore,
we examined whether activation of the NF-kB cascade can induce expression of the
apoptotic pathway, and found that the expression levels of both cleaved (cysteine-dependent
aspartate-directed proteases) CASPASE-3 and CASPASE-8 were significantly increased
after treatment with either IL-17 or a combination of TNF-α and INF-γ (Figure 5 b).
Furthermore, Western blot analysis confirmed that encapsulation of MSCs in alginate
hydrogel in vitro significantly reduced the activation of NF-kB cascades in BMMSCs in
comparison to BMMSCs seeded within ACS and treated with either IL-17 or a combination
of TNF-α and INF-γ, which showed decreased expression levels of p-NF-kB (Figure 3c).
We next implanted BMMSCs subcutaneously into WT mice for 3 or 7 days with alginate
hydrogel, PEGMDA hydrogel or ACS scaffolds, followed by histoimmunofluorescence
analyses. We found that levels of the apoptotic pathway proteases CASPASE-3 and
CASPASE-8 increased significantly between postimplantation days 3 and 7 in the ACS
group with macroporous structure (Figure 5d–g). However, the expression levels of both
CASPASE-3 and CASPASE-8 were significantly lower in the alginate and PEGDMA
hydrogel groups than in the ACS group (P < 0.05), indicating that the encapsulating
hydrogel (e.g., alginate or PEGDMA) can protect BMMSCs from this apoptotic cascade
(Figure 5d–g).
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2.6. Indomethacin Treatment Rescued Bone Regeneration Ability of Implanted BMMSCs In
Vitro

Author Manuscript

We further hypothesized that in addition to the inherent protective properties of alginate
hydrogel to block cytokine diffusion and host inflammatory cell infiltration, the biomaterial
can further be modified with an anti-inflammatory agent to protect the encapsulated MSCs
from insults from the host immune system, leading to improved viability and osteogenic
differentiation of encapsulated MSCs in vivo. It has been reported that NF-kB pathway
activation induces COX-2 pathway upregulation.[30–32] To test this hypothesis, we sought to
augment the protective effects of alginate hydrogel with the goal of regulating the local
microenvironment by delivering an immunosuppressive pharmacological agent with antiinflammatory function, and evaluate its effects on MSC-mediated bone regeneration (Figure
S3a,b, Supporting Information). For the immunosuppressive agent we selected
indomethacin, a nonsteroidal anti-inflammatory drug that acts primarily as a COX-2
inhibitor and thus can inhibit the function of pro-inflammatory cytokines.[33–37] To confirm
the effect of indomethacin when delivered along with MSCs encapsulated in alginate
hydrogel, we treated BMMSCs with either Th1 or Th17 pro-inflammatory T-lymphocytes
alone or combined with indomethacin. We found that pro-inflammatory T-lymphocytes
served to inhibit osteogenesis by the BMMSCs in vitro, as reported in our other experiments
discussed here. In contrast, indomethacin treatment rescued osteogenesis in a dosedependent manner, as indicated by Alizarin red staining of mineralized nodules (Figure
6a,b). Western blot analysis was used to identify the expression of the osteogenic genes ALP
and RUNX2 after treatment with pro-inflammatory T-lymphocytes. We found that the
addition of indomethacin significantly rescued their expression in a dose-dependent manner
(Figure 6c,d).

Author Manuscript

2.7. Indomethacin Treatment Rescued Bone Regeneration Ability of Implanted BMMSCs in
WT Mouse Model

Author Manuscript

Our data prompted us to examine the effects of indomethacin on BMMSC-mediated bone
regeneration in vivo. Using two different approaches, namely subcutaneous implantation
and a critical-size calvarial defect model in WT mice, we found that implantation of
BMMSCs with alginate and indomethacin (50 μg mL−1) resulted in improved bone
regeneration in the ectopic site, as well as improved bone formation in the calvarial defect
area, compared to BMMSCs and alginate without indomethacin or alginate alone (Figure
7a–d). Histological analysis confirmed that the addition of indomethacin significantly
improved bone formation when compared to BMMSCs and alginate without indomethacin
or alginate alone (Figure 7e–h). Furthermore, the levels of the Prostaglandin E2 were
evaluated in the local tissues and peripheral blood using a Prostaglandin E2 ELISA Kit two
days after subcutaneous implantation of BMMSC alginate constructs with or without
indomethacin in WT mice. The results confirmed that the anti-inflammatory drug,
indomethacin, exerts its effects in the local tissue without having any systemic effects
(Figure 7 i,j). Moreover, the effects of indomethacin drug on local immune response were
further evaluated using multicolor flow cytometry analysis. Our data demonstrate (Figure
7k) that, during subcutaneous implantation of encapsulated BMMSCs in alginate hydrogel
in WT mice, in presence of indomethacin there was a significant decrease (P < 0.05) in the
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number of Th1 and Th17 cells in comparison to specimens without indomethacin. These in
vivo data corroborated the results of our mechanistic studies, in which we found that
protection of implanted BMMSCs from insult by host pro-inflammatory cytokines and cells
leads to significant improvement in bone tissue regeneration. To test the potential
translational value of these findings, we used indomethacin treatment to inhibit functions of
pro-inflammatory cytokines (Figure S3c,3g, Supporting Information), and found a
significant improvement in the bone regeneration capacity of BMMSCs (Figure S3e,f,
Supporting Information).

3. Discussion

Author Manuscript

MSCs hold great promise to change the face of regenerative medicine. However, an
important limitation to clinical application of MSCs is immunological rejection by host
immune cells and pro-inflammatory cytokines. Previous work has demonstrated that stem
cell-mediated bone regeneration is partially controlled by the local microenvironment,
including the presence of growth factors, recipient immune cells and cytokines.[7] In
particular, pro-inflammatory T cells are able to inhibit MSC-mediated bone regeneration
through IFN-γ-induced downregulation of osteogenesis regulators and enhancement of TNFα signaling in induced cell apoptosis.[7] In the current study, we demonstrate that proinflammatory T cells and not macrophages MSC-mediated bone regeneration. Macrophages
play an important role in regulation of the inflammatory responses and tissue regeneration.
Recently, it has been reported that hydrogel delivery systems containing macrophage
recruitment agents, are capable of enhance the bone regeneration in animal models.[51]

Author Manuscript
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It is well known that the anti-inflammatory effect of indomethacin is through inhibition of
COX-2 activity and therefore inhibition of prostaglandin synthesis.[38,39] Studies have
shown that PGE2 can regulate multiple aspects of inflammation and multiple functions of
different immune cells.[40] It has been generally recognized as a mediator of active
inflammation, promoting local vasodilatation and local attraction and activation of
neutrophils, macrophages, and mast cells at early stages of inflammation.[41] In addition, it
has been reported that PGE2 can promote the development of IL-17-producing T cells,
which is related to PGE2 ability to suppress the production of IL-12p70 (Th17-inhibitory)
while enhancing the Th17-supporting IL-23.[42,43] Other studies have confirmed that
induction of COX-2 expression lead to the production of prostaglandins (PGE2) that will
enhance IL-17 synthesis leading to inflammation and tissue breakdown.[44] In the current
study, we demonstrate that administration of indomethacin, locally not systemically,
significantly reduced the number of the Th1 and Th17 cells in the local microenvironment
that well correlated to the viability and osteogenic differentiation of implanted MSCs.
Another beneficial effect of the anti-inflammatory drugs (e.g., indomethacin), which is more
important in the later stages of transplantation, is their inhibitory effects on formation of
fibrotic cell layers and collagen deposition on the surface of transplanted microspheres,
hence, enhancing the viability and function of the encapsulated MSCs in a broad range of
cell-based therapeutics.[45,46] Therefore, local administration of anti-inflammatory drugs via
hydrogel delivery vehicles can be used as a strategy to mitigate host immune response and
improve the stability of implantable biomedical devices.[47]
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In studying the role of biomaterials in the MSC-host immune system interplay, hydrogel
biomaterials (e.g., alginate) carry specific advantages. Hydrogel materials allow control over
the amount and spatial presentation of MSCs during and after delivery, enabling us to
perform systematic examination of the effects of the alginate hydrogel on this
interplay.[48–50] In comparison to other biomaterials, such as HA/TCP or ACS, hydrogel
biomaterials can encapsulate MSCs, and may thus act as a physical barrier between the cells
and the host immune system. Here we demonstrated that by encapsulating MSCs in an
RGD-coupled alginate 3D scaffold, we can provide an appropriate physiochemical
microenvironment for enhanced MSC adhesion and viability, and in addition, we are be able
to protect the MSCs from the host immune system via physical separation in the early stages
of transplantation. This protective property is exerted through hindering the infiltration of
pro-inflammatory cytokines and cells. Moreover, the presence of the encapsulating
biomaterial prevents and delays the direct cell-to-cell contact, which enhances cell viability
and function.[44]
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Additionally, it has been shown that the mechanical properties of the encapsulating hydrogel
including modulus influence stem cell viability and fate.[11–15] We observed the same
phenomenon in the current study and based on our empirical data, it was decided to utilize
alginate hydrogel with intermediate stiffness (E = 22 kPa) in order to achieve the lowest
diffusion rate and therefore the greatest protection for the encapsulated MSCs to promote
osteogenic differentiation. Furthermore, we confirmed that scaffold morphology, in terms of
pore-size is another crucial parameter to be considered in the stem cell-immune cell
interplay. Alginate or PEGDMA hydrogel with nanoporous structure can hinder the
penetration of pro-inflammatory cytokines and cells while providing adequate transport of
nutrients and oxygen leading to improved cell viability and osteogenesis. Our results
confirmed the possibility of extending and improving MSC viability and, therefore,
correspondingly improving the tissue regeneration capacity of MSCs by encapsulating them
in a 3D scaffold, which protects them from host immune cells and cytokines. In addition, by
incorporating indomethacin in our MSC delivery system, tested in a WT animal model, we
further regulated the host local microenvironment, leading to additional improvements in the
tissue regeneration capacity of the encapsulated MSCs.

4. Conclusions
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Taken together, these findings substantially extend current knowledge concerning the role of
biomaterials in MSC-mediated tissue regeneration and provide a new strategy for enhanced
bone regeneration in MSC-mediated therapies. We also demonstrate that an alginate
hydrogel scaffold protects MSCs by regulating the interplay between the MSCs and the host
immune system in MSC-mediated bone tissue engineering, thereby providing a molecular
and cellular basis for improving the application of hydrogels in stem cell-based therapies.

5. Experimental Section
Animals
All the animal experiments were performed in accordance with Institutional Animal Care
and Use Committee (IACUC)-approved small animal protocols (11327 and 11953) at the
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University of Southern California. Female C57BL6J and immunocompromised nude (Beige
nu/nu XIDIII) mice were purchased from Jackson Laboratories and Harlan Laboratories,
respectively. In each of the animal experiments five mice (N = 5) were used for each group.
Progenitor Cell Isolation, Culture and Encapsulation

Author Manuscript

Human BMMSCs, processed from marrow aspirates of normal human adult volunteers (20–
35 years of age), were utilized. SHED were harvested and cultured according to published
protocols with Institutional Review Board (IRB) approval from the University of Southern
California (HS 07-00701).[52] The cells were cultured for two weeks with alpha minimum
essential medium (MEM) (Invitrogen) supplemented with 50% fetal bovine serum (FBS), 2
× 10−3 M l-glutamine (Invitrogen), 100 × 10−6 M ascorbic acid-2-phosphate (Wako
Chemicals USA), 100 U mL−1 penicillin, and 100 g mL−1 streptomycin (Invitrogen). Flow
cytometric analysis was performed to ensure that the BMMSCs and SHED were positive for
MSC surface markers CD73, CD146, CD166, and Sca-1 and negative for hematopoietic cell
markers CD31, CD34, and CD45 (BD Biosciences, San Jose, CA). Passage four cells were
used in all the experiments.
Biomaterials Fabrication and Cell Encapsulation
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Custom-made RGD-coupled alginate (Mw: 150 kDa, G/M ≥ 1.5, Nova Matrix, Norway) was
utilized after charcoal treatment and oxidization (2%) using Sodium Periodate (Sigma, St.
Louis, MO), to increase its degradability by production of hydrolytically labile bonds,
according to previously published methods.[53,54] Next, the alginate solution was filtered
through sterile 0.22 μm filters (Millipore, Billerica, MA). BMMSCs or SHED were
encapsulated in the RGD-coupled alginate at different cell densities. The alginate hydrogel
microspheres formation was accomplished by extruding alginate-MSC droplets through a
syringe into a solution of 100 × 10−3 M calcium chloride (CaCl2). The alginate droplets
cross-linked and formed microspheres. The constructs were formed microspheres at 37 °C
for 45 min to form completely cross-linked spheres and then washed three times in
nonsupplemented Dulbecco’s Modified Eagle’s medium (DMEM). No appearance of stem
cells in each well, confirmed the encapsulation of the stem cells to the hydrogel spherical
construct. Alginate microspheres without cells were used as negative controls. ACS
(Helicote, Plainsboro, NJ), a nonencapsulating carrier biomaterial, was used as a control
MSC delivery vehicle. Commercially available poly (ethylene glycol) dimethacrylate
(PEGDMA with average Mn: 550, Sigma) was sterilized under UV light overnight,
dissolved in 10 mL PBS and 100 μL Pen/strep. 200 μL of 5% photoinitiator (2-Hydroxy-4′(2-hydroxyethoxy)-2-methylpropiophenone, Sigma) solution in 100% ethanol was added to
PEGDMA solution and MSC were mixed with PEG at 2 × 106 cells mL−1. A total of 500 μL
of cell/PEG solution was loaded and polymerized for 10 min using 365 nm long wavelength
UV light.
Biomaterial Mechanical Properties Characterization and Effects on Permeability and
Encapsulated MSC Differentiation
The compressive moduli of alginate hydrogels with different calcium ion concentrations
were determined according to methods already in the literature.[21] The Young’s modulus of
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the hydrogel was then determined using the slope of the stress–strain curve at low strain.
Additionally, the release profiles of bovine serum albumin (BSA, 67 kDa, Sigma)
incorporated into alginate microspheres with different degrees of elasticity were determined.
To measure the BSA diffusion out of alginate hydrogel, alginate microspheres were
immersed in PBS solution and the amount of released protein was analyzed with a UV
spectrophotometer at 320 nm (Beckman, Brea, CA) at time points up to two weeks.
Additionally, BMMSCs were encapsulated in RGD-coupled alginate hydrogels with
different elastic modulus (5–50 KPa) and utilized in an in vitro osteogenic analysis. After 4
weeks of osteogenesis, the degree of the osteo-differentiation was analyzed using xylenol
orange (XO, a fluorescent probe which distinguishes the presence of calcified deposits) and
analysis of ALP levels using a colorimetric p-nitro-phenyl phosphate assay according to
manufacturer’s instructions (Abcam, Cambridge, MA).

Author Manuscript

Permeability Analysis of Alginate Hydrogels In Vitro
The permeability of the alginate hydrogel and PEGDMA to two representative cytokines,
TNF-α and IL-17, was evaluated in vitro with ACS being used as the control scaffold.
Scaffolds were immersed for 3 or 7 days in a 2 mL solution containing 200 μg mL−1 of
either IL-17 or TNF-α. The amount of each cytokine that diffused into the tested scaffolds
was tracked over time using fluorescent microscopy utilizing antibodies against IL-17 and
TNF-α (Abcam). Additionally, the concentrations of cytokines (TNF-α, IL17) infiltrated
into each scaffold were measured using IL-17 and TNF-α ELISA (enzyme-linked immuno
assay) kits (both from BioLegend, San Diego, CA) after 3 and 7 days.
Evaluation of the Shielding Properties of Encapsulating Scaffold In Vivo
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Encapsulated BMMSCs (2 × 106) were transplanted subcutaneously into the dorsal surface
of WT mice (C57BL/6). The specimens were harvested after 3 or 7 days and the degree of
the penetration of pro-inflammatory T-lymphocytes was analyzed immunofluorescently
using CD3, CD4, IL-17, and CD146 (MSC marker) antibodies (counterstained with DAPI)
using confocal laser scanning microscopy (CLSM). BMMSCs seeded within ACS or
encapsulated in PEGDMA hydrogel were used as controls.
Cell Apoptosis Evaluation
BMMSCs (0.5 × 106) were seeded on six-well culture plates and cocultured with Pan-T or
Th-17 cells for 3 days. BMMSC apoptosis was analyzed using FACSCalibur (BD
Bioscience) flow cytometric evaluation by staining the cells with Annexin V-PE Apoptosis
Detection Kit I (BD Bioscience).
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In Vitro Osteogenic Differentiation of MSCs in the Presence of pro-inflammatory Cytokines
BMMSCs were cultured in osteogenic medium for 4 weeks. Three types of cytokines: IL-17
(20 ng mL−1), IFN-γ (50 ng mL−1), TNF-α (20 ng mL−1) (BioLegend, San Diego CA) were
added to the osteogenic culture medium every 3 days. After 4 weeks of osteogenic
induction, the cultures were stained with Alizarin red. The expression levels of Runx2 and
ALP (Santa Cruz Biosciences, Dallas, TX) were assayed by Western blot.
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Effects of Immune Cells on Bone Regenerative Properties of Encapsulated MSCs In Vivo
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Pan T cells, CD4+ CD25− T-lymphocytes, CD4 + CD25 + Foxp 3+ Treg lymphocytes, and
macrophages were isolated according to previously published methods.7 Subsequently,
encapsulated BMMSCs or SHED (2 × 106 cells mL−1 alginate) were subcutaneously
transplanted into immunocompromised mice. Approximately 1 × 106 of each of the isolated
immune cells (PanT, Th17, and macrophage) were suspended in 200 μL PBS and injected
into the mice via the tail vein immediately prior to the surgical procedure. Additionally,
encapsulated BMMSCs or SHED (2 × 106 cells mL−1 alginate) were subcutaneously
transplanted into C57BL/6 mice and ≈1 × 106 Tregs were suspended in 200 μL PBS and
injected into the mice via the tail vein immediately prior to the surgical procedure. Eight
weeks after transplantation, the implants were harvested and the amount of bone
regeneration was quantified using radiographic examination, micro-CT, and histological
analyses. For comparison, ACS and HA/TCP scaffolds were used as the control. When the
implants were harvested at 1, 5, 7, or 14 days, the concentrations of cytokines (IFN-γ, TNFα, IL17) were measured using mouse IFN-γ, TNF-α (eBioscience, San Diego, CA), and
Il-17 ELISA kits (Invitrogen).
Development of MSC-Based Drug Delivery System
RGD-coupled alginate as mentioned above was dissolved in deionized water (1% w/v) and
prepared as mentioned before. Next, alginate was mixed with indomethacin (Sigma) at
0.25%, 0.5%, or 1% (w/v) under rigorous stirring overnight. MSCs were encapsulated in
alginate according to the methods mentioned earlier.
In Vitro Drug Release
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Ten alginate microspheres (containing 0.25%, 0.5%, or 1% (w/v) of indomethacin) with
predetermined weight and volume were suspended in 5 mL of PBS (pH = 7.4). The solution
was stirred at 50 rpm using a magnetic stirrer and maintained at 37 °C. At several time
points (0–100 h), 2 mL of the sample was removed and the amount of released indomethacin
was analyzed with a UV spectrophotometer at 320 nm (Beckman, Brea, CA). The same
volume of fresh medium was introduced to replace the withdrawn sample.
Analysis of Effects of Indomethacin Administration on MSC Survival In Vitro

Author Manuscript

BMMSCs (1 × 106) encapsulated in alginate hydrogel with indomethacin (50 μg mL−1) were
cultured in the presence of select inflammatory cytokines Il-10 (20 ng mL−1), or Il-17 (20 ng
mL−1), or TNF-α (20 ng mL−1) combined with IFN-γ (50 ng mL−1) for 2 days. After 48 h of
culturing, the apoptotic MSCs were detected by staining with antibodies against Annexin VPE (BD Pharmingen). The control group did not have any indomethacin added. Also,
encapsulated BMMSCs containing indomethacin (50 μg mL−1) were cultured in osteogenic
media in the presence of select inflammatory cytokines Il-10 (20 ng mL−1), or Il-17 (20 ng
mL−1), TNF-α (20 ng mL−1) combined with IFN-γ (50 ng mL−1) for two weeks. The ALP
concentrations were measured using a colorimetric p-nitro-phenyl phosphate assay (Abcam).
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In Vitro Osteogenic Differentiation Assay: Effects of Administration of Indomethacin
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BMMSCs (0.2 × 106) were cocultured under osteogenic culture conditions in the presence of
Th17 cells (1 × 106). To study the effect of the anti-inflammatory drug on osteogenesis,
indomethacin (at a dose of 10 or 50 μg mL−1) was added to the osteogenic differentiation
media every 3 days. After 4 weeks of treatment the samples were stained with Alizarin red.
Also, the expression levels of Runx2 and ALP were assayed by Western blot according to
the methods mentioned earlier. The same experiment was conducted in the presence of CD3
activated T cells. In order to study the protective properties of the encapsulating hydrogel,
encapsulated BMMSCs containing indomethacin (at a dose of 10 or 50 μg mL−1) were
cultured in osteogenic media in the presence of Th17 cells, and after 4 weeks of culturing,
the samples were stained with antibodies against ALP. In addition, after dissolving the
alginate microspheres in citrate buffer (6% w/v, PH = 7.4) and extracting the protein, the
expression levels of Runx2 and ALP were examined by Western blot. MSCs without
indomethacin and samples without Th17 cells were used as the control groups.
BMMSC-Mediated Bone Formation: Effects of Administration of Indomethacin
Approximately 2.0 × 106 BMMSCs were encapsulated in alginate hydrogel containing
indomethacin and subcutaneously implanted into the dorsal surface of C57BL/6J mice.
Eight weeks after implantation, the implants were harvested. Micro-CT analysis and H&E
staining of the histological sections were evaluated using the NIH ImageJ software. MSC
hydrogel constructs were implanted subcutaneously in immunocompromised mice as
positive control, while the constructs without indomethacin or without BMMSCs were used
in WT mice as the negative controls.
Calvarial Bone Defect Model in C57BL/6J Mice: Effects of Administration of Indomethacin
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Approximately 4 × 106 BMMSCs were encapsulated in alginate hydrogel containing
indomethacin and implanted into 5 mm diameter defects in the calvaria of C57BL/6J mice
according to previously published methods.7 MSCs encapsulated in alginate without
indomethacin and alginate hydrogel alone were used as controls. To study the role of the
anti-inflammatory agent in vivo, the cytokine levels in the implants were measured. Briefly,
4 × 106 BMMSCs were encapsulated in alginate hydrogel containing indomethacin and
transplanted into 5 mm diameter defects in the calvaria of C57BL/6J mice.
Cytokine Levels in BMMSC-Mediated Bone Formation: Effects of Administration of
Indomethacin
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The implants were harvested at different time points (1, 3, 7, and 14 days) and the levels of
cytokines (IFN-γ, TNF-α, IL17) were measured using mouse IFN-γ, TNF-α (eBioscience,
San Diego, CA), and IL-17 ELISA kits (Invitrogen).
Measurement of Local and Systemic PGE2 Levels
BMMSCs (2.0 × 106) were encapsulated in alginate hydrogel containing indomethacin and
subcutaneously implanted into the dorsal surface of C57BL/6J mice. Two days after
implantation, the specimens were retrieved for local measurements of PGE2 levels. The
retrieved specimens with the attached tissue were prepared, centrifuged, and the supernatant
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solutions were used for the prostaglandin E2 assay. The prostaglandin E2 concentration was
then assayed using Prostaglandin E2 ELISA Kit (Abcam). Additionally, The plasma levels
of PGE2 were measured using ELISA assay following manufacturer’s instructions (Abcam).
Multicolor Flow Cytometry
Approximately 2.0 × 106 BMMSCs were encapsulated in alginate hydrogel containing
indomethacin and subcutaneously implanted into the dorsal surface of C57BL/6J mice. Two
days after implantation, the specimens were retrieved. Present Th1 and Th17 cells were
identified and quantified using FITC (fluorescein isothiocyanate)- and PE-labeled antibodies
against CD3, INF-γ, and Il-17.
Statistical Analysis of Data
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As appropriate, data were analyzed statistically by means of a Student’s t test, Mann–
Whitney U test, analysis of variance (ANOVA), or Kruskal–Wallis test. P < 0.05 was
considered significant. SPSS 16.0 was used for statistical analysis of data.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Host pro-inflammatory T-lymphocytes and cytokines inhibit BMMSC-mediated bone
regeneration. a) Microtomography or corresponding histological b) analyses of bone
regeneration after ≈2 × 106 BMMSCs encapsulated into 1 mL of RGD-coupled alginate and
were subcutaneously implanted into immunocompromised mice (a1,b1), C57BL/6 WT mice
(a2,b2), or transplanted with HA/TCP into C57BL/6 WT mice (a3,b3), and analyzed after 8
weeks. The role of pro-inflammatory cells on bone formation was tested by supplementing
immunocompromised mice with ≈1 × 106 each of previously isolated PanT a4,b4), Th17
a5,b5), or macrophage (MQ) a6,b6) immune cells, with each cell type suspended in 200 μL
PBS and injected into the host mice via the tail vein immediately prior to surgically
implanting the BMMSC-alginate construct. Bone formation by the alginate-encapsulated
BMMSCs could be partially rescued by supplementing the C57BL/6 WT host with 1 × 106
isolated Treg cells suspended in 200 μL PBS injected via the tail vein immediately prior to
surgically implanting the BMMSC-alginate construct. Subcutaneous engraftment of
BMMSCs encapsulated in alginate hydrogel in immunocompromised mice showed the
greatest amount of bone formation compared to WT hosts, with increased bone production
in WT hosts supplemented with Treg cells. pro-inflammatory T cells, but not macrophages,
diminished bone production. RGD-coupled alginate alone showed no bone regeneration
(a8,b8). c) Shown in (a1–a8) are samples subjected to bone volume (BV) fraction
measurement derived from BV/total volume (TV) as assessed by micro-CT or d) bone
volume/total area identified by histomorphometric analysis. Scale bars: b), 200 μm; Alg =
alginate; B = Bone; CT = connective tissue. Each error bar represents the standard deviation;
NS = not significant; * P < 0.05 and *** P < 0.001. Kruskal–Wallis test was utilized to
compare and analyze the obtained data.
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Figure 2.
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The encapsulating biomaterial hinders the infiltration of pro-inflammatory cytokines.
Characterization of the permeability of fabricated algi-nate microspheres or PEGDMA
hydrogel to a,b) IL-17 or c,d) TNF-α using immunofluorescence techniques.
Immunofluorescence staining showed infiltration of pro-inflammatory cytokines IL-17 (a) or
TNF-α (c) is reduced in alginate or PEGDMA (c) compared to d) ACS after 3 or 7 days of
implantation, respectively. The fluorochrome signal from each sample approximates the
infiltration of each cytokine and the respective intensity value is shown in the bar graphs for
(c) and (d), respectively. e) ELISA analysis showed that the concentration of Il-17 and TNFα infiltrated into each hydrogel after 3 and 7 days were significantly lower than that of ACS
as the control. Scale bars: a,c) 100 μm. Each error bar represents the standard deviation (n =
7, seven independent specimens were tested in each group.); NS = not significant; * P <
0.05. Two-way (time × material) ANONA test was utilized to compare and analyze the
obtained data.
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Encapsulating hydrogel reduces apoptosis of implanted BMMSCs via reduction of proinflammatory T-lymphocyte penetration leading. Encapsulated BMMSCs (2 × 106 cells
mL−1 of RGD-coupled alginate as well as PEGDMA) were subcutaneously implanted into
WT mice. After 3 or 7 days, the specimens were retrieved and the presence of Th17 (CD4+,
IL-17+) cells, Pan-T (CD+3) cells, and cells expressing Annexin V-PE (apoptosis marker)
and CD-146 (MSC marker) within the microspheres were detected by immunofluorescence
labeling with their respective antibody and coun-terstaining with DAPI using CLSM. a,b)
CD4- and IL-17 double immunofluorescence staining showed reduced Th17 cell infiltration
in alginate (or PEGDMA) hydrogel in comparison to the ACS group after 3 or 7 days of
implantation in WT mice. c,d) Immunofluorescence staining showed decreased infiltration
of CD3+ T lymphocytes in alginate (or PEGDMA) hydrogel in comparison to ACS matrix
after 3 or 7 days of implantation (white arrows indicate CD3+ cells). e,f) CD146 and
Annexin V double immunofluorescence staining showed reduced apoptosis of BMMSCs
encapsulated in alginate (or PEGDMA) hydrogel compared to BMMSCs implanted with
ACS as the carrier 3 or 7 days postimplantation in WT mice. No statistically significant
difference was observed in any of the experiments between either of the used hydrogels.
Scale bars: a), 200 μm; c, e), 100 μm. Each error bar represents the standard deviation; * P <
0.05 and *** P < 0.001. Two-way (time × material) ANONA test was utilized to compare
and analyze the obtained data.
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Pro-inflammatory cytokines induce BMMSC apoptosis and reduce their osteogenic capacity.
a) The rate of MSC apoptosis using an Annexin V-PE apoptosis detection kit was performed
on 0.2 × 106 BMMSCs cocultured separately with 1 × 106 of either Pan-T or Th17 cells.
After 3 days of culture, FACS (fluorescence activated cell sorting) analysis showed
increased apoptosis of BMMSCs after pro-inflammatory T-cell coculture. b) The in vitro
inhibitory effects of pro-inflammatory cytokines on osteogenic differentiation was shown by
BMMSCs (0.2 × 106) cultured under osteogenic conditions for 2 weeks with inflammatory
cytokines [IL-17 (10 ng mL−1), IFN-γ 50 (ng mL−1), and TNF-α (5 ng mL−1)] added to the
osteogenic culture medium every 3 days. Alizarin red staining revealed reduced mineralized
nodule formation. c) Western blot analysis showed that pro-inflammatory cytokine-treated
BMMSCs expressed reduced levels of select osteogenic markers including RUNX2 and
ALP. β-Actin was used as a protein loading control. Each error bar represents the standard
deviation; * P < 0.05, and *** P < 0.001. Two-way (time × material) ANONA test was
utilized to compare and analyze the obtained data.
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Pro-inflammatory cytokines activated CASPASE-dependent apoptotic pathway through NFkB cascades in BMMSCs. To confirm the deleterious effects of pro-inflammatory cytokines
on MSC survival and dissect the molecular mechanism of action, 0.5 × 106 BMMSCs were
cocultured separately with IL-17 or with IFN-γ in combination with TNF-α for 3 days.
Pathway activation was analyzed through Western blotting for NF-kB, IKKβ, CASPASE-3,
and CASPASE-8 antibodies. a) Western blot analysis revealed evidence for activated NF-kB
cascades in BMMSCs after pro-inflammatory cytokine treatment compared to controls. b)
Western blot analysis demonstrated more activated CASPASE-3 and CASPASE-8 in
BMMSCs after pro-inflammatory cytokine treatment than in controls. c) BMMSCs (1 × 106)
were encapsulated in alginate or seeded onto ACS, then cocultured with IL-17 or a
combination of IFN-γ with TNF-α for 3-days. Western blot analysis showed downregulation
of apoptosis-related proteins CASPASE-3 and CASPASE-8 for BMMSCs encapsulated in
alginate hydrogel in comparison to cells seeded on ACS. d,e) To corroborate these in vitro
results in an in vivo environment, BMMSCs (2 × 106 cells mL−1 alginate or PEGDMA)
were subcutaneously implanted into WT mice. Immunofluorescence staining with antibodies
against CASPASE-3 and CASPASE-8 of specimens retrieved at 3 or 7 days after
implantation showed significantly higher CASPASE-3 expression in MSCs implanted in
ACS compared to MSCs encapsulated in alginate or PEGDMA hydrogels. f,g)
Immunofluorescence staining showed higher CASPASE-8 expression in MSCs grown on
ACS in comparison to alginate or PEGDMA hydrogels after 3 or 7 days of implantation in
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WT mice. Scale bars: d,f), 200 μm. Each error bar represents the standard deviation; * P <
0.05, and *** P < 0.001. Kruskal–Wallis test was utilized to compare and analyze the
obtained data.
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Indomethacin treatment rescued bone regeneration ability of implanted BMMSCs in vitro.
To test whether local administration of the anti-inflammatory drug indomethacin improves
MSC-mediated bone regeneration, 0.2 × 106 BMMSCs were cocultured under osteogenic
culture conditions in the presence of either 1 × 106 CD-3 activated T-lymphocytes or Th17
lymphocytes for 2 days. Indomethacin (10 or 50 μg mL−1) was added to the osteogenic
differentiation media. After 2 weeks of treatment the samples were stained with Alizarin red
for detection of calcium deposits, and RUNX2 and ALP expression levels were assayed by
Western blot. a) Indomethacin treatment improved osteogenesis of BMMSCs cocultured
with Th17 cells under osteoinductive conditions. b) Indomethacin treatment rescued
osteogenesis of BMMSCs cocultured with CD-3 activated T lymphocytes under
osteoinductive conditions. c) BMMSCs treated with CD-3 activated T-lymphocytes or Th17
lymphocytes expressed reduced levels of the osteogenic markers RUNX2 and ALP, while
indomethacin treatment significantly increased the expression of the same osteogenic
markers, as assessed by Western blot analysis. Each error bar represents the standard
deviation (n = 7, seven independent specimens were tested in each group); * P < 0.05, ** P
< 0.01, and *** P < 0.001. ANOVA test was utilized to compare and analyze the obtained
data.

Adv Funct Mater. Author manuscript; available in PMC 2015 June 24.

Moshaverinia et al.

Page 24

Author Manuscript
Author Manuscript
Author Manuscript

Figure 7.
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Indomethacin treatment rescued bone regeneration ability of implanted BMMSCs in mouse
model. To corroborate the in vitro effects of indomethacin in vivo, 4 × 106 BMMSCs were
encapsulated in alginate hydrogel containing indomethacin (50 μg mL−1) and implanted
subcutaneously or in a 5 mm diameter calvarial defect in WT mice. a,b) Implantation of
BMMSCs encapsulated in alginate hydrogel loaded with indomethacin (50 μg mL−1)
revealed increased bone regeneration at the ectopic site, shown by micro-CT and histologic
analysis (c,d). e,f) Increased bone regeneration was observed at the calvarial defect,
compared to groups that received BMMSC-alginate constructs without indomethacin or
alginate alone. g) Bone volume fraction (BV/TV) was assessed by micro-CT images in e,h)
bone volume/total area identified by histomorphometric analysis of the retrieved specimens
based on (f). i) ELISA analysis showing the reduced concentration of prostaglandin E2
(PGE2) in subcutaneous transplants in WT mice in presence of indomethacin. However, no
difference was found in the levels of PEG2 in peripheral blood in presence or absence of
indomethacin (j). k) Multicolor flow cytometric analysis showed significant decrease in the
number of Th1 and Th17 cells in the retrieved subcutaneous specimens in the presence of
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indomethacin. Alg = alginate; B = Bone; CT = connective tissue. Scale bars: a), 200 μm; g),
500 μm (high mag), 50 μm (low mag). Each error bar represents the standard deviation; * P
< 0.05, ** P < 0.01, and *** P < 0.001. Kruskal–Wallis test and Mann–Whitney U test were
utilized for (a–h) and (i–j), respectively. T-test was used for k) to compare and analyze the
obtained data.
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